Title : BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Pub. Date : 2019 Feb

PMID : 30425037






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. rucaparib BRCA1 DNA repair associated Homo sapiens
2 Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P < 0.0001). rucaparib BRCA1 DNA repair associated Homo sapiens
3 SIGNIFICANCE: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. rucaparib BRCA1 DNA repair associated Homo sapiens